Loading stock…

The Clorox Company (CLX) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

CLXThe Clorox

Revenue FY26$6.7B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+14%7

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+22%8

EPS growth, FY28E+9%6

EPS growth, FY29E+6%5

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 6%/yr from here.

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK8 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-13%3

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-27%2

3-year return-25%2

5-year return-40%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -40% over five), behind 80% of the market.

It's down 27% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%), over three months (-13%) and so far this year (-14%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Clorox. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CLXThe Clorox

Revenue FY26$6.7B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+14%7

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+22%8

EPS growth, FY28E+9%6

EPS growth, FY29E+6%5

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 6%/yr from here.

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK8 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-13%3

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-27%2

3-year return-25%2

5-year return-40%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -40% over five), behind 80% of the market.

It's down 27% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%), over three months (-13%) and so far this year (-14%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Clorox. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

The Clorox Company

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Clorox. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Clorox. Get the full investment case.

Premium